Abstract
Abbreviations: HCW, health-care worker; SARS, severe acute respiratory syndrome.
It should not be a surprise that the SARS coronavirus is different from previous members of this genus, as the behaviour of the pathogen differs markedly from human coronaviruses described previously. The virus may have acquired a conserved motif, s2m, from avian infectious bronchitis virus but, apart from this, there is no evidence of any exchange of genetic material with non-Coronaviridae (Marra et al., 2003; Rota et al., 2003). This is consistent with the hypothesis that a previously unknown animal coronavirus has recently mutated, developing the ability to productively infect humans. There are some indications that the civet cat, eaten as a delicacy in southern China, was the source animal.
Not only did this virus differ genetically from other coronaviruses isolated in humans, but it behaves differently from other human coronaviruses and most other respiratory pathogens. The mortality rate appears to be very high (Tsang et al., 2003; Lee et al., 2003). Elderly patients with pre-existing respiratory complaints are especially vulnerable. This must be compared with acute community-acquired pneumonia, which has an approximate case fatality rate of 5 % for those patients admitted to hospital, but this represents the tip of a substantial iceberg of clinical disease managed in the community with negligible mortality. It is not yet known whether some patients may be infected with the SARS agent and develop few or no symptoms. Only when these data are available will it be possible to calculate an accurate case mortality rate. However, it is likely that the mortality rate of this infection is over 10 % (Booth et al., 2003). In view of its ability to spread in the hospital environment to health-care workers (HCW), it is likely that SARS will alter medical practice in many ways.
Some patients, like the index patient at the hotel in Hong Kong, appear to shed large amounts of virus, resulting in a very large number of secondary cases. These patients have been described in other viral infections such as Ebola haemorrhagic fever (Khan et al., 1999) and are termed super-spreaders'. This epidemiological model assumes that there is no asymptomatic carrier state and, although there is no evidence of such a state, it has been noted that, in some outbreaks, there are mild cases of infection (Poutanen et al., 2003). This difference has been ascribed to age, genetic predisposition, smoking, previous immunity and co-infection with another pathogen. Should it be found that asymptomatic carriage occurs, control of the SARS coronavirus is going to be extremely difficult.The route of transmission seems to be via aerosolized droplets. The portal of entry is thought to be inhalation or contact with mucous membranes and/or conjunctiva. Virus is also present in faeces, and about 25 % of patients complain of diarrhoea (Zhao et al., 2003; Lee et al., 2003; Poutanen et al., 2003). The high attack rate in medical staff is probably a function of the stage at which patients present and the production of virus-containing aerosol when medical procedures (such as suction and intubation) are undertaken without adequate protection (Donnelly et al., 2003).
Transmission to health-care workers (HCW)
One of the biggest concerns around the spread of SARS has been the high rate of infections amongst HCW and in health-care settings. In the Greater Toronto area, 111 of the 144 cases admitted to hospital had exposure to SARS in a hospital, and 73 (51 %) were HCWs (Booth et al., 2003). In Hong Kong, among 138 cases of secondary and tertiary spread, 85 (62 %) involved HCWs (Lee et al., 2003). Most of this spread was prior to the recognition of the aerosol, environmental and fomite spread of the virus. This has led to specific recommendations of nursing of suspected cases in negative-pressure isolation or a single side room. Protocols have been set up for patients meeting the clinical case-definitions to be recognized early and isolated appropriately. HCWs in contact with patients have adopted specific infection-control measures, including the use of face masks with filter efficiencies of 95 % or above, use of gloves and eye and head protection (Seto et al., 2003) and careful attention to hand-washing. Not since the advent of HIV have such stringent infection-control procedures been adopted so universally by HCWs. However, despite these measures, there have been reports of transmission to HCWs in the intensive-care setting (Hong Kong Department of Health, 2003). This is thought to be as a result of aerosol-generating procedures like non-invasive ventilation, endotracheal intubation, open tracheal suction, use of nebulizers and bronchoscopy. The recognition that there is a significant increase in viraemia in the second week of the illness (Peiris et al., 2003) and that patients requiring intensive care may therefore have high levels of circulating virus support this increased risk. Moreover, it is now apparent that the virus can survive for over 24 h outside the body on environmental surfaces (WHO, 2003a). This has led to many treatment centres minimizing or avoiding certain high-risk procedures and adopting protocols that include the use of hood respirators with a filtered air-supply for unavoidable procedures. Such equipment is expensive and requires extensive training to gown and de-gown safely and, unless teams are comfortable with and fully versed in their use, this may lead to increased risk of contamination. A recent report of the investigation of one series of such transmission in Canada highlights the need for appropriate training in the execution of existing infection-control procedures (Health Canada, 2003).
Incubation period ranges from 2 to 10 days and early symptoms are fever, myalgia and headache. Fever appears to be almost universal and is often the presenting feature, although some patients present with mild respiratory symptoms (Booth et al. 2003). The respiratory phase starts after 37 days, with a dry cough and dyspnoea. In some patients, hypoxia develops and progressive pulmonary infiltrates appear on the chest X-ray. In China, this has been called the blossoming flower lesion. The infiltrates are typically peripheral and a study using thin-section CT has shown this, together with a characteristic crazy-paving appearance due to thickening of interlobular septa (Wong et al., 2003). Some patients develop respiratory failure and require ventilation. This presents considerable cross-infection control problems (see above). There is some evidence that non-invasive methods of ventilation may be associated with a better outcome, but there are concerns that this approach to ventilation may be associated with the generation of aerosols and an increased risk of viral transmission (Zhao et al., 2003).
In some patients, the illness is biphasic in that, 47 days after defervescence of pyrexia, new infiltrates appear on X-ray and respiratory failure worsens; these patients often do badly. Consistent laboratory findings are a thrombocytopenia and leucopenia, which particularly affects lymphocytes. Consistent with virus replication in organs other than lung is the elevation of creatine kinase, lactate dehydrogenase and liver transaminases (Tsang et al., 2003; Booth et al., 2003). In a multivariate analysis, the independent predictors of an adverse outcome were advanced age (odds ratio per decade of life, 1.80; 95 % confidence interval, 1.162.81; P = 0.009), a high peak lactate dehydrogenase level (odds ratio per 100 U l-1, 2.09; 95 % confidence interval, 1.283.42; P = 0.003) and an absolute neutrophil count that exceeded the upper limit of the normal range on presentation (odds ratio, 1.60; 95 % confidence interval, 1.032.50; P = 0.04) (Lee et al., 2003).
Diagnosis
The laboratory tests that can be applied for routine diagnosis are PCR and immunofluorescent ELISA detection of serum antibodies using SARS coronavirus from Vero cell culture. Early efforts at the University of Hong Kong using random RT-PCR provided 646 bp of genomic sequence, from which a diagnostic PCR was developed (Peiris et al., 2003). Parallel efforts in Hamburg yielded three fragments that, when sequenced, did not overlap with a 400 bp fragment reported the day before (24 March 2003) by the CDC (Drosten et al., 2003). Nested primers were designed by the Hamburg group within the orflab region, which encodes the viral replicase 1B (Marra et al., 2003). The Hamburg group found five of the patients with probable SARS studied to be positive with all of their primers, both nested and non-nested. Only three of 13 suspected patients were positive. The group also developed a real-time quantitative PCR that showed that the concentration of viral RNA was highest in sputum and low in nose and throat swabs, suggesting that sputum is the best diagnostic sample. The index patient had very high viral loads [8.3 x 106 virus copies (ml sputum)-1]. This fits with the highly infectious nature of patients at presentation. Low levels of virus were found on day 9 in serum, suggesting a long viraemic phase and replication of the virus outside the respiratory tract (exemplified by deranged liver function tests). Viral RNA was also found in the faeces of patients late in convalescence, a feature of other coronaviruses (Cho et al., 2001). Extended testing of patients and contacts for antibody to SARS coronavirus will be important in the future to delineate spread and to identify asymptomatic carriage. The CDC group also developed RT-PCR and an ELISA as well as IFA for antibody detection (Ksiazek et al., 2003). Through the efforts of the WHO, a standardized PCR protocol is now available in participating national reference laboratories.
Outcome
One study has determined a more accurate estimate of the case fatality rate than initial work early in the epidemic. Depending on the statistical method used, mortality in < 60-year-old patients was 13.2 or 6.8 % and, for > 60 years, 43.3 or 55.0 % (Donnelly et al., 2003). This rate was higher than the cumulative rates given previously by the WHO and local authorities. One of the explanations is that the study was able to allow for new patients that had been added to the denominator but that had not yet experienced mortality.
In order for the case-definitions to remain a valid tool, daily reporting of probable cases and areas reporting community transmission have been collated by WHO and disseminated via their website (http://www.who.ch). After early spread of the disease to Hong Kong, Singapore, Vietnam and Canada, travel warnings restricting travel to affected areas were issued by the WHO and exit screening was introduced for travellers from these areas (WHO, 2003b). Although the incubation period of the illness is short (Donnelly et al. 2003) and transmission is only believed to occur after the onset of symptoms, the effectiveness of such measures is yet to be determined.
At national and local levels, strenuous control measures, in addition to infection control around known cases, have been adopted. In areas where community transmission has been reported, vigorous public education in reporting symptoms, early isolation of possible cases, exhaustive contact tracing and isolation and quarantine measures were introduced, often requiring emergency legislation. As the epidemic has evolved, the possibility of an environmental source of transmission of SARS coronavirus has become apparent. At the end of March 2003, 320 cases of SARS were reported amongst the residents of Amoy Gardens, a block of apartments in Hong Kong, where sewage contamination was the likely source of infection. Closures of buildings, hospitals and schools and markets have been required. The economic impact of such measures will be enormous, but there have been successes. Vietnam was the first affected country to terminate community and hospital transmission successfully. Canada and the Philippines were next to declare control of the infection (but see below), since followed by Singapore. Unfortunately, in China and Taiwan, the epidemic continues to grow.
The situation in the UK
In the UK, the Health Protection Agency, via the SARS co-ordinating committee, has been instrumental in formulating and implementing a public health strategy for protecting the population from SARS. This includes reporting of suspected cases, contact tracing and surveillance of cases and contacts. As of May 2003, up to eight probable cases and more than 150 suspected cases had been reported in the UK. Apart from one, all the probable cases have had contacts abroad. Four of these cases have subsequently been discarded on the basis of an alternative diagnosis and only one of the remaining probable cases has had a coronavirus infection confirmed by serology (Health Protection Agency, 2003).
The clinical features of SARS are now well recognized. Many of the characteristic features were described in early reports (Tsang et al., 2003; Booth et al., 2003). Treatment remains supportive; early hopes that ribavirin would be effective (Koren et al., 2003) have not been borne out by experience (Zhao et al., 2003). The use of corticosteroids, particularly at high doses, is important and two studies, one with 31 patients and the other with 190, support this action (So et al., 2003; Zhao et al., 2003). Much effort will doubtless be expended in developing antiviral agents in the future. The major protease of SARS coronavirus is a potential target and has been expressed in Escherichia coli (Anand et al., 2003). Preliminary characterization shows that it retains many of the structural motifs found in other coronavirus proteases. Molecular modelling suggests that inhibitors such as AG7088 would serve as good lead compounds for development of specific antivirals.
China was the source of SARS coronavirus and remains the worst affected country, with 5013 of the world's 7447 cases on 12 May 2003. Almost half (252) of the total deaths (552) have also been there. Spread of SARS from the developed cities of the eastern coastal region to inland rural areas may make control and eradication much harder. Reports that SARS has been identified in Hebei, Anhui, Guangxi and Henan (Parry, 2003) are worrying. The latter province is estimated to have 1 million HIV carriers, and the interaction of this virus with individuals with an attenuated immune system is another great unknown in the rapidly unfolding SARS story. There are encouraging reports that the epidemic is being controlled, but the difficulties experienced in Toronto (WHO, 2003a), with a new outbreak after the epidemic was declared over, mean that we cannot be complacent about controlling this new threat to public health.References
- Booth, C. M., Matukas, L. M., Tomlinson, G. A. & 18 other authors (2003). Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto area. JAMA 289, 28012809.
[Abstract/Free Full Text]
- CDC (2003). Updated interim surveillance case definition for Severe Acute Respiratory Syndrome (SARS) United States, April 29, 2003. Morbid Mortal Weekly Rep 52, 391393.[Medline]
- Cho, K. O., Hoet, A. E., Loerch, S. C., Wittum, T. E. & Saif, I. J. (2001). Evaluation of concurrent shedding of bovine coronavirus via the respiratory tract and enteric route in feedlot cattle. Am J Vet Res 62, 14361441.[CrossRef][Medline]
- Donnelly, C. A., Ghani, A. C., Leung, G. M. & 16 other authors (2003). Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361, 1761. 1761.[CrossRef][Medline]
- Drosten, C., Günther, S., Preiser, W. & 22 other authors (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348, 19671976.
[Abstract/Free Full Text]
- Fouchier, R. A., Kuiken, T., Schutten, M. & 7 other authors (2003). Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423, 240. 240.[CrossRef][Medline]
- Health Canada (2003). Health Canada statement on release of Health Canada and the US Centers for Disease Control and Prevention preliminary report. Published online 15 May 2003. http://www. hc-sc.gc.ca/english/media/releases/2003/sars_statement.htm
- Health Protection Agency (2003). SARS update laboratory testing shows confirmed case. Published online 15 May 2003. http://www.hpa.org.uk/news/150503_sars.htm
- Hong Kong Department of Health (2003). Outbreak of severe acute respiratory syndrome (SARS) at Amoy Gardens, Kowloon Bay, Hong Kong. Main findings of the investigation. Published online 17 April 2003. http://www.info.gov.hk/info/ap/pdf/amoy_e.pdf
- Hsu, L.-Y., Lee, C.-C., Green, J. A. & 7 other authors (2003). Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 9, 713717.[Medline]
- Khan, A. S., Tshioko, F. K., Heymann, D. L. & 16 other authors (1999). The re-emergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995.Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179 (Suppl. 1), S76S86.
- Koren, G., King, S., Knowles, S. & Phillips, E. (2003). Ribavirin in the treatment of SARS: a new trick for an old drug? Can Med Assoc J 168, 12891292.
[Free Full Text]
- Ksiazek, T. G., Erdman, D., Goldsmith, C. S. & 23 other authors (2003). A novel coronavirus associated with severe acute respiratory syndrome.SARS Working Group. N Engl J Med 348, 19531966.
[Abstract/Free Full Text]
- Lee, N., Hui, D., Wu, A. & 11 other authors (2003). A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348, 19861994.
[Abstract/Free Full Text]
- Marra, M. A., Jones, S. J. M., Astell, C. R. & 56 other authors (2003). The genome sequence of the SARS-associated coronavirus. Science 300, 13991404.
[Abstract/Free Full Text]
- Parry, J. (2003). SARS in China spreads from Beijing to poorer inland provinces. BMJ 326, 1056. 1056.
[Free Full Text]
- Peiris, J. S. M., Lai, S. T., Poon, L. L. M. & 13 other authors (2003). Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319. 1319.[CrossRef][Medline]
- Poutanen, S. M., Low, D. E., Henry, B. & 17 other authors (2003). Identification of severe acute respiratory syndrome in Canada. N Engl J Med 348, 19952005.
[Abstract/Free Full Text]
- Rota, P. A., Oberste, M. S., Monroe, S. S. & 32 other authors (2003). Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 13941399.
[Abstract/Free Full Text]
- Seto, W. H., Tsang, D., Yung, R. W., Ching, T. Y., Ng, T. K., Ho, M., Ho, L. M. & Peiris, J. S. (2003). Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 361, 15191520.[CrossRef][Medline]
- So, L. K., Lau, A. C. W., Yam, L. Y. C., Cheung, T. M. T., Poon, E., Yung, R. W. H. & Yuen, K. Y. (2003). Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 361, 16151617.[CrossRef][Medline]
- Tsang, K. M., Ho, P. L., Ooi, G. C. & 13 other authors (2003). A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348, 19771985.
[Abstract/Free Full Text]
- WHO (2003a). First data on stability and resistance of SARS coronavirus compiled by members of WHO laboratory network. Published online 4 May 2003. http://www.who.int/csr/sars/survival_2003_05_04/en/ index.html
- WHO (2003b). Severe acute respiratory syndrome: change in status in Toronto (Canada). WHO Wkly Epidemiol Rec 78, 169180.[Medline]
- Wong, K. T., Antonio, G. E., Hui, D. S. C. & 9 other authors (2003). Thin-section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the diseases. Radiology (in press). http://radiology.rsnajnls.org/cgi/content/abstract/2283030541v1
- Zhao, Z., Zhang, F., Xu, M. & 9 other authors (2003). Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 52, 715720.
[Abstract/Free Full Text]
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS